Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Imugene Limited ( (AU:IMU) ) is now available.
Imugene Limited announced the quotation of 5,722,219 ordinary fully paid securities on the Australian Securities Exchange, following the exercise of options or conversion of convertible securities. This development signifies an expansion in the company’s capital resources, potentially enhancing its financial positioning and supporting its ongoing research and development efforts within the competitive biotech industry.
More about Imugene Limited
Imugene Limited operates in the biotechnology industry, focusing primarily on the development of immunotherapies that activate the immune system of cancer patients to treat and eradicate tumors. The company has a strategic market focus on leveraging its in-house developed technologies to target various cancer types.
YTD Price Performance: 50.0%
Average Trading Volume: 158,054
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $198.4M
Learn more about IMU stock on TipRanks’ Stock Analysis page.
